NFKB1 and lung carcinoma: DCS shows more inhibition on lung cancer cell growth in vitro and in vivo, possibly by down‐regulating p38 and JNK MAPK signalling molecules, while simultaneously inhibiting IκB, NF‐κB phosphorylation and pro‐inflammatory cytokines.